Oxford Biomedica Revenue 2024

The Oxford Biomedica Revenue history

YEAR	REVENUE (undefined GBP)	GROSS MARGIN (%)
2027e	245.94	16,15
2026e	211.36	18,80
2025e	169.34	23,46
2024e	133.27	29,81
2023	89.54	44,37
2022	139.99	49,42
2021	142.8	57,87
2020	87.73	52,52
2019	64.06	44,24
2018	66.78	65,91
2017	37.59	50,94
2016	27.78	57,39
2015	15.91	63,30
2014	13.62	67,57
2013	5.38	78,81
2012	7.76	91,37
2011	7.72	92,75
2010	11.15	105,38
2009	19.12	97,70
2008	18.39	92,99
2007	7.22	93,77
2006	0.76	100,00
2005	0.82	4844,76
2004	0.5	7945,40

Oxford Biomedica Aktienanalyse

What does Oxford Biomedica do?

Oxford BioMedica PLC is a biopharmaceutical company based in Oxford, England. The company was founded in 1995 and has since become a leading provider of gene therapy products. The company's business model is to develop, produce, and market gene therapies for rare diseases and cancer. Oxford BioMedica utilizes modern technologies, such as viral vectors, to introduce genetic material into diseased cells and correct their function. One of the company's main areas of focus is the development of gene therapies for rare diseases. Oxford BioMedica has several promising products in this field, including gene therapies for metabolic disorders, muscular diseases, and eye diseases. Another important area for the company is the development of cancer immunotherapies. Oxford BioMedica is working on the development of gene therapies that activate the body's immune system to specifically target cancer cells. Among the products that Oxford BioMedica has already brought to market is the gene therapy product Strimvelis, which is used to treat severe combined immunodeficiency (SCID). Through treatment with Strimvelis, children with SCID can lead a normal life and are no longer confined to sterile environments. Another well-known product from Oxford BioMedica is the gene therapy product OXB-102, which is being tested in phase III clinical trials for the treatment of Parkinson's disease. In this therapy, a viral vector is used to correct a genetic mutation in the affected brain cells and alleviate the symptoms of Parkinson's. In recent years, Oxford BioMedica has also formed significant partnerships with major pharmaceutical and biotech companies such as Novartis, Sanofi, and Bioverativ to further develop and bring its gene therapy technology and products to market. Overall, Oxford BioMedica is a leading company in the field of gene therapy. With a strong pipeline of promising products and significant partnerships with the pharmaceutical industry, the company is well positioned to continue growing and contribute to the cure of diseases. Oxford Biomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Oxford Biomedica's Sales Figures

The sales figures of Oxford Biomedica originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Oxford Biomedica’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Oxford Biomedica's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Oxford Biomedica’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Oxford Biomedica Stock

How much revenue did Oxford Biomedica generate this year?

Oxford Biomedica has achieved a revenue of 133.27 M GBP this year.

How much was the turnover of the company Oxford Biomedica compared to the previous year?

The revenue of Oxford Biomedica has increased by 48.84% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Oxford Biomedica?

The revenue of Oxford Biomedica is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Oxford Biomedica measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Oxford Biomedica so important for investors?

The revenue of Oxford Biomedica is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Oxford Biomedica pay?

Over the past 12 months, Oxford Biomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oxford Biomedica is expected to pay a dividend of 0 GBP.

What is the dividend yield of Oxford Biomedica?

The current dividend yield of Oxford Biomedica is .

When does Oxford Biomedica pay dividends?

Oxford Biomedica pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oxford Biomedica?

Oxford Biomedica paid dividends every year for the past 0 years.

What is the dividend of Oxford Biomedica?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oxford Biomedica located?

Oxford Biomedica is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oxford Biomedica kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oxford Biomedica from 5/28/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did Oxford Biomedica pay the last dividend?

The last dividend was paid out on 5/28/2024.

What was the dividend of Oxford Biomedica in the year 2023?

In the year 2023, Oxford Biomedica distributed 0 GBP as dividends.

In which currency does Oxford Biomedica pay out the dividend?

The dividends of Oxford Biomedica are distributed in GBP.